Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261


Masoud Tavazoie
Masoud Tavazoie, M.D., Ph.D.
Chief Executive Officer & Co-founder

Masoud is co-founder, Board Director, and the Chief Executive Officer of Rgenix.

David Darst
David Darst, M.B.A.

David co-leads Rgenix’s financing, corporate development, and drug development efforts.

Robert Wasserman, M.D.
Chief Medical Officer

Bob oversees clinical development of Rgenix’s first-in-class programs.

Isabel Kurth
Isabel Kurth, Ph.D.
VP of Research

Isabel leads Rgenix’s research and target discovery efforts.

Stephen Wald, MS
Stephen Wald
VP of Chemistry & Pharmaceutical Sciences

Steve is responsible for chemical, analytical and formulation development, and manufacturing scale-up, of Rgenix’s drug candidates.

Foster Gonsalves
Foster Gonsalves, Ph.D., M.P.H.
VP of Drug Development & Strategy

Foster heads preclinical development at Rgenix. Prior to joining Rgenix, Foster was a management consultant within the life sciences practice

Corey Sohmer
Corey Sohmer, M.B.A.
VP of Finance & Accounting

Corey brings to Rgenix more than 25 years of progressive leadership experience in finance and accounting.

Michael Szarek
Michael Szarek, Ph.D.
VP of Clinical & Regulatory Affairs

Michael leads clinical and regulatory affairs at Rgenix.